Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])[C@H](C[C@@]23C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])OC[C@@H](O)[C@H](O)[C@H]6O)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=LLPWNQMSUYAGQI-OOSPGMBYSA-N
InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Notoginsenoside R1 is a characteristic constituent of Radix notoginseng, a well known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as diabetic nephropathy, cardiovascular disease, cerebral vascular disease, and liver dysfunction. Notoginsenoside R1 has multiple pharmacologic activities, including cardioprotective, neuroprotective, anti-inflammatory, and anticancer effects. A study on the application of Notoginsenoside R1 in a rat model of diabetic nephropathy indicated that Notoginsenoside R1 ameliorated the glucose-induced impairment of podocyte adhesive capacity and subsequent podocyte depopulation, partly through the upregulation of α3β1 integrin via PI3K-Akt signaling pathway activation.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. | 1997 Mar |
|
| Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly. | 2009 Jul |
|
| Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo. | 2014 |
|
| Notoginsenoside R1 attenuates atherosclerotic lesions in ApoE deficient mouse model. | 2014 |
|
| ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. | 2014 Dec 15 |
|
| Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. | 2014 Sep |
|
| Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. | 2015 Feb |
|
| Estrogen receptor α mediates the effects of notoginsenoside R1 on endotoxin-induced inflammatory and apoptotic responses in H9c2 cardiomyocytes. | 2015 Jul |
|
| Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs. | 2016 |
Patents
Sample Use Guides
Notoginsenoside R1 was administrated orally at doses 5, 10 and 20 mg/kg•day to rats with diabetic nephropathy. Notoginsenoside R1was administered during 16 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: High glucose decreased podocyte adhesive capacity and α3β1 integrin expression, the main podocyte anchoring dimer to the glomerular basement membrane. However, Notoginsenoside R1 ameliorated impaired podocyte adhesive capacity and partially restored α3β1 integrin protein and mRNA expression.
Treatment with 10 and 100 μg/ml of Notoginsenoside R1 for 24 hours significantly increased the adhesion of podocytes to basement membrane protein complex
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:38:45 GMT 2023
by
admin
on
Sat Dec 16 09:38:45 GMT 2023
|
| Record UNII |
Z62692362Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z62692362Z
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
DTXSID101036451
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
80418-24-2
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
8111
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
441934
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
